Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Plasma cell 1Lymphoid 1

Conditions

Glioblastoma 41Central Nervous System Neoplasms 32Gliosarcoma 29Brain Neoplasms 28Astrocytoma 28Glioma 20Oligodendroglioma 16Ependymoma 6Medulloblastoma 4Neuroectodermal Tumors, Primitive 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Neoplasms 2Neoplasm Metastasis 2Meningioma 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Familial ependymoma 2Choroid Plexus Neoplasms 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Vasculitis, Central Nervous System 1Testicular Neoplasms 1Stiff-Person Syndrome 1

Interventions

Temozolomide 19Bevacizumab 14Irinotecan 12Carboplatin 10Cyclophosphamide 9Radiosurgery 8Lomustine 8Radiotherapy 7pembrolizumab 6Vincristine 6Topotecan 6Drug Therapy 6Surgical Procedures, Operative 5Etoposide 5Doxorubicin 5Cisplatin 53-Iodobenzylguanidine 5trametinib 4Metformin 4Gemcitabine 4Dexamethasone 4Blood Specimen Collection 4poly ICLC 3dabrafenib 3Vorinostat 3Trastuzumab 3Therapeutics 3Radiation 3Paclitaxel 3Observation 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Carmustine × CNS × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT00761280 2014-11-14

SAPPHIRE

Isarna Therapeutics GmbH

Phase 3 Terminated
27 enrolled 28 charts
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡